ПСИХОНЕВРОЛОГИЧЕСКИЕ ЭФФЕКТЫ ЭСЛИКАРБАЗЕПИНА АЦЕТАТА

1. Калинин В.В., Железнова Е.В. Противосудорожные и психотропные свойства антиэпилептических препаратов при лечении больных эпилепсией. М. 2008.

2. Полянский Д.А. Клинико-терапевтические факторы риска суицидального поведения у больных эпилепсией. Автореферат канд. мед. наук. М. 2003; 30.

3. Borges Gonçalves E., Cendes F. Depression in patients with refractory temporal lobe epilepsy. Arq Neuropsiquiatr. 2011; 69 (5): 775-777.

4. Eddy M., Hugh E. Rickards, Andrea E. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011; 4 (6): 385-407.

5. Elger C. et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009; 50 (3): 454-463.

6. Hufnagel A., Ben-Menachem E., Gabbai A.A. et al. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year openlabel extension study. Epilepsy Res. 2013; 103: 262-269.

7. Kanner A.M. Depression and Epilepsy: A New Perspective on Two Closely Related Disorders. Epilepsy Currents. September/October 2006; 6 (5): 141-146.

8. Lambert M.V., Robertson M.M. Depression in Epilepsy: Etiology, Phenomenology and Treatment. Epilepsia. 1999; 40 (10): 21-47.

9. Milovan D. et al. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy & Behavior. 2010; 18: 366-373.

10. Nashef L., Mohanraj R. et al. Eslicarbazepine acetate: who needs it? A Progress in Neurology and Psychiatry Supplement. January 2013.

11. Shorvon S.D., Reynolds E.H. Monotherapy or polytherapy for epilepsy? Epilepsia. 1981; 22: 1-10.